Peter Lawson

Stock Analyst at Barclays

(1.18)

# 3,359

Out of 4,814 analysts

99

Total ratings

33.33%

Success rate

-17.67%

Average return

Main Sectors:

Top Industries:

Biotechnology Diagnostics & Research

Stocks Rated by Peter Lawson

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	IOVA Iovance Biotherapeutics	Maintains: Overweight	$22 → $5	$3.07	+62.87%	6	Apr 14, 2025
	BMEA Biomea Fusion	Maintains: Equal-Weight	$11 → $3	$1.70	+76.47%	5	Apr 2, 2025
	TCRX TScan Therapeutics	Maintains: Overweight	$14 → $3	$1.44	+108.33%	2	Mar 7, 2025
	GERN Geron	Maintains: Overweight	$9 → $4	$1.27	+216.21%	1	Feb 27, 2025
	EXEL Exelixis	Maintains: Equal-Weight	$25 → $29	$36.06	-19.58%	5	Feb 13, 2025
	ARVN Arvinas	Maintains: Overweight	$48 → $32	$8.60	+272.09%	7	Feb 3, 2025
	RCUS Arcus Biosciences	Maintains: Overweight	$25 → $29	$7.90	+267.32%	6	Oct 25, 2024
	RVMD Revolution Medicines	Maintains: Overweight	$54 → $60	$36.75	+63.27%	3	Sep 27, 2024
	RLAY Relay Therapeutics	Maintains: Overweight	$14 → $17	$2.70	+530.80%	5	Sep 10, 2024
	SNDX Syndax Pharmaceuticals	Maintains: Overweight	$32 → $33	$11.51	+186.71%	4	Aug 15, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$92 → $66	$28.54	+131.25%	2	Aug 9, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$9 → $8	$1.27	+529.92%	8	Jul 31, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$75 → $105	$84.69	+23.98%	10	Jul 29, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$20 → $31	$9.32	+232.62%	2	Jul 15, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$13 → $17	$7.96	+113.57%	3	Jun 7, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$18 → $13	$1.31	+896.17%	1	May 24, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$47 → $63	$37.89	+66.27%	3	Feb 29, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$6 → $10	$1.12	+792.86%	3	Feb 27, 2024
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Underweight	$2 → $1	$0.24	+312.03%	2	Aug 10, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Equal-Weight	$7 → $5	$0.84	+492.98%	4	Aug 4, 2023
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$210 → $120	$5.06	+2,273.89%	2	Aug 5, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Overweight	$30	$7.35	+308.16%	1	Jul 28, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Overweight	$7 → $3.5	$0.65	+435.99%	4	Jul 7, 2022
	XXXX XXXXXXXXXXXXXXXX Upgrade	Maintains: Underweight	$355 → $365	$71.16	+412.93%	1	Aug 6, 2021
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Overweight	$46	$27.66	+66.31%	2	Oct 22, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Underweight	$28	$9.69	+188.96%	1	Mar 4, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Overweight	$30	$0.64	+4,587.50%	1	Mar 4, 2020
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Buy	$17 → $45	$1.29	+3,401.95%	2	Jan 23, 2018
	XXXX XXXXXXXXXXXXXXXX Upgrade	Upgrades: Buy	$16 → $45	$37.76	+19.17%	2	Jan 23, 2018
	XXXX XXXXXXXXXXXXXXXX Upgrade	Initiates: Buy	$70	$0.73	+9,489.04%	1	Jul 14, 2017

Iovance Biotherapeutics

Apr 14, 2025

Maintains: Overweight

Price Target: $22 → $5

Current: $3.07

Upside: +62.87%

Biomea Fusion

Apr 2, 2025

Maintains: Equal-Weight

Price Target: $11 → $3

Current: $1.70

Upside: +76.47%

TScan Therapeutics

Mar 7, 2025

Maintains: Overweight

Price Target: $14 → $3

Current: $1.44

Upside: +108.33%

Geron

Feb 27, 2025

Maintains: Overweight

Price Target: $9 → $4

Current: $1.27

Upside: +216.21%

Exelixis

Feb 13, 2025

Maintains: Equal-Weight

Price Target: $25 → $29

Current: $36.06

Upside: -19.58%

Arvinas

Feb 3, 2025

Maintains: Overweight

Price Target: $48 → $32

Current: $8.60

Upside: +272.09%

Arcus Biosciences

Oct 25, 2024

Maintains: Overweight

Price Target: $25 → $29

Current: $7.90

Upside: +267.32%

Revolution Medicines

Sep 27, 2024

Maintains: Overweight

Price Target: $54 → $60

Current: $36.75

Upside: +63.27%

Relay Therapeutics

Sep 10, 2024

Maintains: Overweight

Price Target: $14 → $17

Current: $2.70

Upside: +530.80%

Syndax Pharmaceuticals

Aug 15, 2024

Maintains: Overweight

Price Target: $32 → $33

Current: $11.51

Upside: +186.71%

Aug 9, 2024

Maintains: Overweight

Price Target: $92 → $66

Current: $28.54

Upside: +131.25%

Jul 31, 2024

Maintains: Overweight

Price Target: $9 → $8

Current: $1.27

Upside: +529.92%

Jul 29, 2024

Maintains: Equal-Weight

Price Target: $75 → $105

Current: $84.69

Upside: +23.98%

Jul 15, 2024

Maintains: Overweight

Price Target: $20 → $31

Current: $9.32

Upside: +232.62%

Jun 7, 2024

Maintains: Overweight

Price Target: $13 → $17

Current: $7.96

Upside: +113.57%

May 24, 2024

Maintains: Overweight

Price Target: $18 → $13

Current: $1.31

Upside: +896.17%

Feb 29, 2024

Maintains: Overweight

Price Target: $47 → $63

Current: $37.89

Upside: +66.27%

Feb 27, 2024

Maintains: Overweight

Price Target: $6 → $10

Current: $1.12

Upside: +792.86%

Aug 10, 2023

Maintains: Underweight

Price Target: $2 → $1

Current: $0.24

Upside: +312.03%

Aug 4, 2023

Maintains: Equal-Weight

Price Target: $7 → $5

Current: $0.84

Upside: +492.98%

Aug 5, 2022

Maintains: Overweight

Price Target: $210 → $120

Current: $5.06

Upside: +2,273.89%

Jul 28, 2022

Initiates: Overweight

Price Target: $30

Current: $7.35

Upside: +308.16%

Jul 7, 2022

Maintains: Overweight

Price Target: $7 → $3.5

Current: $0.65

Upside: +435.99%

Aug 6, 2021

Maintains: Underweight

Price Target: $355 → $365

Current: $71.16

Upside: +412.93%

Oct 22, 2020

Upgrades: Overweight

Price Target: $46

Current: $27.66

Upside: +66.31%

Mar 4, 2020

Initiates: Underweight

Price Target: $28

Current: $9.69

Upside: +188.96%

Mar 4, 2020

Initiates: Overweight

Price Target: $30

Current: $0.64

Upside: +4,587.50%

Jan 23, 2018

Upgrades: Buy

Price Target: $17 → $45

Current: $1.29

Upside: +3,401.95%

Jan 23, 2018

Upgrades: Buy

Price Target: $16 → $45

Current: $37.76

Upside: +19.17%

Jul 14, 2017

Initiates: Buy

Price Target: $70

Current: $0.73

Upside: +9,489.04%